Your Volume Is Up. Your Cash Isn't.

Radiology CFO Intelligence — profit and cash by center, by modality, by payer and by claim, for independent multi-center imaging groups.

Independent imaging centers are winning demand faster than their back offices can convert it into cash. We compress the referral → auth → scan → claim → paid cycle, separate your PET Tracer Unit from your Radiology Unit, and turn billing-company activity into economic outcomes your lender will fund — profit and cash read by center, by modality, by payer, by tracer and by claim. Engagements run remotely off the systems you already have; our current imaging work spans Florida and Texas. This is the intelligence your accountant and your billing company will not build for you.

Proof

Anonymized from active Benefique engagements. Specific client context available under NDA on the Review readout.

See the reporting before you share a file

A complete worked example of an imaging engagement, built on a fictional composite group with synthetic figures: net revenue per scan by center, days to cash by payer rail, and the full report library.

What We Do for Radiology Groups

Six named capabilities delivered inside every engagement. Each one solves a problem generic accounting and billing reports cannot.

PET Tracer Economics

Two Business Unit decomposition separating high-reimbursement PET Tracer Scans from general radiology. Per-payer, per-tracer, per-facility toxic-combination detection and referrer strategy.

Collections & Cash Release

Per-payer DSO, aging decomposition, Letter-of-Protection trap analysis, and the billing-fee-versus-DSO trade-off your biller will not run for you.

Payer Mix Analysis

PIP compression modeling, payer grading A–F, and the front-desk selection economics that lock in profitability weeks before billing touches the claim.

Per-Claim Profitability

$/Claim → GP$/Claim → NOI/Claim stack. High-cost procedure economics. Which procedures lose money on which payers — a 9:1 profitability gap on identical work.

Multi-Center COO Scorecard

Quarterly performance framework with gated bonus design, independent assessment, and cross-center benchmarking that holds operators accountable to numbers.

Radiology Tax & R&D

Section 41 R&D credits for imaging groups ($40K–$120K/year typical). S-corp reasonable compensation. Entity structure. 2026 tax law changes.

Intelligence Library

Multi-Site & Scaling Operations

Running more than one center? Portfolio and per-center P&L, COO accountability, and the math of adding the next location.

PET Tracer Economics

The single largest P&L driver in a modern center — and the one most accounting systems blend into invisibility.

Revenue Cycle: A/R, DSO & Billing

Per-payer DSO, aging decomposition, the billing-fee-versus-collections trade-off, and A/R your lender will actually fund.

Payer Mix (Commercial / PI / Self-Pay)

PIP and Letter-of-Protection compression, payer grading A–F, and the front-desk selection economics that lock in profit before billing touches the claim.

Per-Claim Profitability

The $/Claim → GP$/Claim → NOI/Claim stack. Which procedures lose money on which payers — a 9:1 profitability gap on identical work.

M&A & Exit / QofE Readiness

Buying the next center, or getting ready to sell. Valuation logic, deal structure, owner economics, and quality-of-earnings readiness.

Radiology Tax & R&D

Section 41 R&D credits for imaging groups, S-corp reasonable compensation, entity structure, and 2026 tax-law changes.

Frequently Asked Questions

Who is the Strategic Radiology Review for?

Imaging center operators, CFOs, and medical directors running one or more centers with $2M+ revenue who suspect their accountant and billing company cannot answer per-payer, per-tracer, or per-claim profitability questions. Typical profile: growing but cash-constrained, unclear on PET Tracer Scan economics, preparing for a lender conversation, or renegotiating payer contracts.

What are PET Tracer Scans, and why do you separate them?

PET Tracer Scans refers to high-reimbursement specialty tracers with radiopharmaceutical input costs of $2,000–$3,000 per dose and payer reimbursement that varies as much as 9x depending on payer mix. Their economics are structurally different from general radiology (MRI, CT, ultrasound, X-ray, standard PET). Blending them into one "imaging" line hides the single largest profit-and-loss driver in a modern center — which is exactly what most accounting systems do. Our Two Business Unit Framework breaks them apart.

Do you replace our accountant or biller?

No. We sit above both. Your accountant keeps the books. Your biller processes claims. We build the intelligence layer that makes sense of both data sources together — per-payer, per-tracer, per-facility, per-claim. Most engagements run alongside existing accounting and billing relationships.

What does the Strategic Radiology Review deliver?

A banker-grade Intelligence PDF covering Two Business Unit decomposition, PET Tracer economics with toxic-combination detection, per-claim profitability stack, DSO by payer, payer mix risk analysis, and a prioritized action plan with quantified dollar impact. Turnaround is two weeks from data access. A 90-minute executive readout is included.

What is the investment for ongoing CFO work?

It depends on center count, complexity, and scope. We propose specific scope and pricing on the Strategic Review readout — after we have seen your data, not before. This avoids the common trap of buying generic "CFO services" priced by hour or headcount rather than by the problems actually worth solving.

Can you help us prepare for a lender or line-of-credit conversation?

Yes. We have built triple-reconciliation methodologies that align operational billing data, the accounting system, and bank-grade aged receivables — typically within 0.5% variance. This is the difference between a lender funding a seven-figure facility and a lender asking for another quarter of data.